Immunovant, Inc. announced that it has signed a purchase agreement with existing investor Roivant Sciences Ltd. to issue 17,021,276 shares at a price of $11.75 per share for the gross proceeds for $199,999,993 on August 2, 2021. The investor stake has increased from 57.5% to 63.8% stake in the company. The issuance and sale of the Shares is exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933.